Dofetilide , ≥98% , 115256-11-6

Synonym(s):
N-[4-[2-[Methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide;UK-68798

CAS NO.：115256-11-6

Empirical Formula: C19H27N3O5S2

Molecular Weight: 441.56

MDL number: MFCD00869707

EINECS: 638-817-5

PRODUCT Properties

• Melting point: 147-1490C
• Boiling point: 614.1±65.0 °C(Predicted)
• Density: 1.344±0.06 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: DMSO: >20mg/mL
• pka: 7.0, 9.0, 9.6(at 25℃)
• form: powder
• color: white to off-white
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• InChIKey: IXTMWRCNAAVVAI-UHFFFAOYSA-N
• CAS DataBase Reference: 115256-11-6(CAS DataBase Reference)

Description and Uses

Dofetilide was launched in the US as a novel class III antiarrhythmic for treatment of cardiac patients with highly symptomatic atrial fibrillation This bisarylsulfonamide can be obtained by a three step synthesis starting from 4-nitro-N-methylphenethylamine and involving simultaneous nitro reduction and mesylation on both aromatic amine functions. In contrast to other class III antiarrhythmic agents such as amiodarone, dofetilide potently and selectively inhibits a single potassium channel, Ikr, the rapidly acting component of the delayed rectifier potassium current, Accordingly, by blocking the open state of Ikr, dofetilide is able to prolong the effective refractory period (ERP) in both atrial and ventricular myocardium and the monophasic action potential duration. Moreover, as it targets only one cardiac ion channel, it does not produce any effects on the sinus node, cardiac conduction system and other extracardiac organs, making it unique among established class III agents. Several pharmacological studies with models using different animal species indicated that dofetilide was a potent and highly selective class III antiarrhythmic agent devoid of cardiodepressive effects. During clinical trials in patients with paroxysmal atrial or supraventricular fibrillation, dofetilide was found to increase atrial and ventricular refractory periods without affecting conduction or sinus node function. If increases in the QT/QTc interval after oral or intravenous dofetilide are expected, as for other class III antiarrhythmic agents, other electrocardiographic intervals are unaffected.

Dofetilide (90%) , is a potassium channel blocker. Antidysrhythmic drug.

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Danger
• Hazard statements: H302-H360
• Precautionary statements: P201-P202-P264-P270-P301+P312-P308+P313
• Hazard Codes: T,N
• Risk Statements: 61-48/22-51
• Safety Statements: 53-22-36-57
• WGK Germany: nwg
• HS Code: 2935904000
• Hazardous Substances Data: 115256-11-6(Hazardous Substances Data)